de Mingo Marta, Morán Alberto, Sánchez-Pernaute Andrés, Iniesta Pilar, Díez-Valladares Luis, Pérez-Aguirre Elia, de Juan Carmen, García-Aranda Cristina, Díaz-López Antonio, García-Botella Alejandra, Martín-Antona Esteban, Benito Manuel, Torres Antonio, Balibrea José Luis
Department of Surgery, Hospital Clinico San Carlos, Madrid, Spain.
Hepatogastroenterology. 2007 Jan-Feb;54(73):315-9.
BACKGROUND/AIMS: The aim of the present work is to clarify the role of metalloproteinase-9 and its inhibitor in the evolution of gastric cancer after surgical resection.
We have studied 44 gastric cancer patients submitted to surgery. There were 13 proximal tumors, 16 located in the middle third and 15 in the distal one. Overall survival was 26% at 6 years. Metalloproteinase-9 and tissue inhibitor of metalloproteinase concentrations were investigated by means of ELISA in frozen samples of tumoral and normal gastric mucosa.
Mean concentration of metalloproteinase-9 in tumoral tissue was 42 ng/mg of total protein, and this value was 6.9 times greater than the mean concentration in non-tumoral tissue. Cancer tissue also expressed higher levels of TIMP-1, 7.25 versus 4.39 ng/mg of protein. Higher levels of metalloproteinase expression in tumoral tissue, greater [metalloproteinase in tumor]/[metalloproteinase in non-tumor] ratio and greater [metalloproteinase]/[inhibitor] ratio in tumor cells, were all of them statistically related to a worse prognosis when T1 and T2 tumors were considered.
The expression of metalloproteinase-9 or its inhibitor is related to a more aggressive phenotype of gastric cancer.
背景/目的：本研究旨在阐明金属蛋白酶-9及其抑制剂在胃癌手术切除后进展过程中的作用。
我们研究了44例接受手术的胃癌患者。其中13例为近端肿瘤，16例位于胃中部三分之一处，15例位于远端。6年总生存率为26%。通过酶联免疫吸附测定法（ELISA）对肿瘤和正常胃黏膜的冷冻样本进行金属蛋白酶-9和金属蛋白酶组织抑制剂浓度的检测。
肿瘤组织中金属蛋白酶-9的平均浓度为42纳克/毫克总蛋白，该值比非肿瘤组织中的平均浓度高6.9倍。癌组织中TIMP-1的表达水平也更高，分别为7.25纳克/毫克蛋白和4.39纳克/毫克蛋白。当考虑T1和T2期肿瘤时，肿瘤组织中金属蛋白酶表达水平更高、肿瘤组织中[金属蛋白酶]/[非肿瘤组织中金属蛋白酶]比值更大以及肿瘤细胞中[金属蛋白酶]/[抑制剂]比值更大，所有这些均与较差的预后在统计学上相关。
金属蛋白酶-9或其抑制剂的表达与胃癌更具侵袭性的表型相关。
